With Reverse Merger Complete, Transcept Looks To Partner Intermezzo
This article was originally published in The Pink Sheet Daily
Executive Summary
Newly public specialty firm anticipates annual U.S. sales of $600 million for middle-of-night sleep aid.
You may also be interested in...
Financings Of The Fortnight: Biotech IPO Trends Continue With Supernus’ Offering – Haircuts, Insider Buys
Plus news on recent financing activity by Argos, Telstar, Castlight Health and Transcept.
Transcept's Intermezzo Yields To FDA Concerns Over Residual Side Effects
Transcept's low-dose zolpidem for middle-of-the-night awakenings may need additional studies, including driving tests.
Transcept's Intermezzo Yields To FDA Concerns Over Residual Side Effects
Transcept's low-dose zolpidem for middle-of-the-night awakenings may need additional studies, including driving tests.